Amyloid-related imaging abnormalities in Japanese patients with Alzheimer’s disease treated with Lecanemab: A real-world study - 05/04/26
, Atsushi Iwata a, b
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
Although clinical trials have suggested a lower incidence of adverse events associated with Lecanemab in Asian populations compared to global cohorts, longitudinal real-world data across broader clinical indications are necessary to confirm these findings in routine practice.
Objectives |
This study aimed to provide real-world evidence regarding the safety profile of Lecanemab in Japanese patients in a clinical setting.
Design |
A real-world observational study with a follow-up period of up to 18 months.
Setting |
A single center in Japan.
Participants |
We included 120 Japanese patients who received Lecanemab between December 2023 and November 2025 and underwent at least one brain MRI before the fifth infusion.
Measurements |
Safety outcomes included amyloid-related imaging abnormalities (ARIA), infusion-related reactions (IRRs), and treatment discontinuation.
Results |
The mean age was 74.2 ± 7.9 years, and 89 (74%) were female. The majority of patients (88%) had a baseline CDR global score of 0.5. During follow-up, 81 patients completed the 12-month assessment. ARIA occurred in 24 patients (20%); ARIA-E with or without ARIA-H occurred in 5 patients (4%), and isolated ARIA-H occurred in 19 patients (16%). Crucially, no patients experienced symptomatic ARIA. All patients with ARIA-E who had available APOE data were ε4 carriers. Patients with ARIA had significantly lower baseline MMSE scores ( p = 0.04), alongside non-significant trends toward higher plasma GFAP levels ( p = 0.11) and higher deep white matter Fazekas scores ( p = 0.05). IRRs occurred in 34 patients (28%), all of which were mild. Treatment was discontinued in 19 patients (16%), mainly due to disease progression ( n = 8).
Conclusion |
In this Japanese AD cohort, Lecanemab demonstrated a manageable safety profile in a real-world setting. In exploratory analyses, potential trends toward a higher frequency of ARIA were observed in patients with lower MMSE scores, higher plasma GFAP levels, and higher Fazekas scores, underscoring the importance of individualized risk assessment prior to therapy.
Le texte complet de cet article est disponible en PDF.Keywords : Alzheimer’s disease, Lecanemab, Aria, Japanese cohort, Real-world data
Plan
Vol 13 - N° 6
Article 100562- juin 2026 Retour au numéro
Article précédent
- Dementia risk factor assessment in a local Alzheimer’s prevention population: a German cross-sectional, observational study
- Lena Sannemann, Michelle Gerards, Lara Bohr, Frederic Brosseron, Claus Escher, Franziska Kalthegener, Theresa Müller, Alfredo Ramírez, Philip Zeyen, Frank Jessen, Ayda Rostamzadeh
- Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer’s disease with hydromethylthionine mesylate using external control data
- Bjoern O Schelter, Helen Shiells, Serena Lo, Nafeesa Nazlee, Emily Evans, Peter Bentham, Serge Gauthier, Henrik Zetterberg, Gordon K Wilcock, Lutz Froelich, Alistair Burns, Emer MacSweeney, Clive Ballard, Jin-Tai Yu, Tay Siew Choon, Vahe Asvatourian, Natalia Muehlemann, Jan Priel, Karin Kook, Tenecia Sullivan, Diane Downie, Sonya Miller, Carol Pringle, John M․D Storey, Tom Baddeley, Charles R Harrington, Roger Staff, Anca-Larisa Sandu, Claire Hull, Richard Stefanacci, Claude M Wischik, Alzheimer's Disease Neuroimaging Initiative
Bienvenue sur EM-consulte, la référence des professionnels de santé.